11 Jan 2019 Research

Lymphoma: Understanding relapse and treatment resistance

What is this research looking at?

Our immune system is remarkable. It is made up of many different types of immune cells that work together to protect the body from infection by pathogens such as bacteria, viruses and parasites.

We are investigating what happens when a certain type of cell in the immune system, known as B cells, starts growing out of control and develops into blood cancers such as leukaemia, lymphoma and myeloma.

We want to know what happens when B cells mature normally from precursor cells in the bone marrow and discover what has gone wrong when they turn into cancer cells instead.

Considerable success has been achieved in the treatment of lymphoma. However, a significant unmet need remains: roughly 40% of patients either do not respond to treatment or the condition recurs after treatment. Currently, our ability to predict which patients will fail treatment is poor.

By taking a detailed look at B cells as they develop and specialise, we can spot small groups of dangerous cells that are particularly likely to turn into cancer and identify the genetic faults that drive B cells to grow out of control.

We are using our knowledge to create new models for the development of B cells and blood cancers in the lab, so we can find new ways to treat or even prevent these deadly diseases.

Our research uses a model of lymphoma to test the response to treatments and development of resistance. A main advantage of the model is that we can interrogate these questions on a well-defined scenario and can perform iterative tests and predictions. Further, the model generated in this project will allow initial testing of novel treatments.

What could this mean for people with leukaemia?

This research could inform the medical decision of when to use combination and novel therapies for patients with a higher probability of developing resistance to standard treatment, alongside bringing safer treatments to patients.

Official project title: Development of a model system to study diffuse large B cell lymphoma clonal evolution

Related posts

Three leading charities collaborate to fight childhood cancers

2 October 2023

Three leading charities collaborate to fight childhood cancers

New Partnership we3can to fund research into three most common childhood cancers Today (2nd October 2023), three leading cancer charities have launched a new collaboration in order to improve the…

University of Southampton’s Dr Giorgia Chiodin Wins Olive Boles Innovation Award

7 November 2024

University of Southampton’s Dr Giorgia Chiodin Wins Olive Boles Innovation Award

Dr Giorgia Chiodin from the University of Southampton has been awarded the prestigious Olive Boles Innovation Award for 2024. Awarded annually to a Leukaemia UK John Goldman Fellow, this award…

World Blood Cancer Day interview with Dr Pramila Krishnamurthy

18 May 2022

World Blood Cancer Day interview with Dr Pramila Krishnamurthy

On 28th May the global blood cancer community comes together to mark World Blood Cancer Day, this campaign calls for support of those with blood cancer and encourages people to become stem cell donors.

Inquiry highlights the impact of COVID-19 on blood cancer services

11 March 2022

Inquiry highlights the impact of COVID-19 on blood cancer services

A new report has recently been published, following an inquiry by the All-Party Parliamentary Group (APPG) on Blood Cancer and the APPG on Stem Cell Transplantation and Advanced Cellular Therapies, on the impact of Covid-19 on blood cancer services in the UK.